ÖZ
Amaç
Subklinik hipotiroidi (SKH), serum tiroid uyarıcı hormon (TSH) düzeylerinin yüksek, serbest tiroksin (FT4) ve serbest triiyodotironin (FT3) düzeylerinin ise normal olduğu bir durumdur. Bu çalışmanın amacı, SKH hastalarında serum adropin düzeylerini değerlendirmektir.
Yöntemler
Bu prospektif kesitsel çalışmaya 41 SKH hastası ve 43 ötiroid kontrol dahil edildi. Katılımcıların tiroid fonksiyon testleri, biyokimyasal parametreleri ve serum adropin düzeyleri ELISA yöntemi ile ölçüldü. Gruplar istatistiksel olarak karşılaştırıldı.
Bulgular
Gruplar arasında yaş, cinsiyet ve vücut kitle indeksi açısından anlamlı fark saptanmadı (p>0,05). SKH grubunda serum adropin düzeyi kontrol grubuna göre anlamlı olarak düşük bulundu (136,75±41,87 ng/mL’ye karşı 220,65±64,93 ng/mL; p<0,001). Adropin ile TSH arasında anlamlı negatif korelasyon saptandı (r=-0,765; p<0,001). FT3 ve FT4 ile anlamlı korelasyon izlenmedi.
Sonuç
SKH'li hastalarda serum adropin düzeyi anlamlı derecede düşüktür. Adropin, SKH'de kardiyometabolik riskin değerlendirilmesinde potansiyel bir biyobelirteç olabilir.
Anahtar Kelimeler:
Adropin, subklinik hipotiroidi, metabolik sendrom, insülin direnci
Kaynaklar
1Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012;122:3035-43.
2McAninch EA, Bianco AC. Thyroid hormone signaling in energy homeostasis and energy metabolism. Ann N Y Acad Sci. 2014;1311:77-87.
3Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379:1142-54.
4Ku EJ, Yoo WS, Chung HK. Management of subclinical hypothyroidism: a focus on proven health effects in the 2023 Korean Thyroid Association Guidelines. Endocrinol Metab (Seoul). 2023;38:381-91.
5McDermott MT, Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab. 2001;86:4585-90.
6Krysiak R, Marek B, Okopień B. Subkliniczna niedoczynność tarczycy [Subclinical hypothyroidism]. Wiad Lek. 2008;61:139-45.
7Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: a review. JAMA. 2019;322:153-60.
8Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the heart. Methodist Debakey Cardiovasc J. 2017;13:55-9.
9Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010;122(11 Suppl):S185-92.
10Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8:468-81.
11Jasaszwili M, Billert M, Strowski MZ, Nowak KW, Skrzypski M. Adropin as a fat-burning hormone with multiple functions-review of a decade of research. Molecules. 2020;25:549.
12Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63.
13Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116:1725-35.
14Paschou SA, Bletsa E, Stampouloglou PK, Tsigkou V, Valatsou A, Stefanaki K, et al. Thyroid disorders and cardiovascular manifestations: an update. Endocrine. 2022;75:672-83.
15Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol. 2017;14:39-55.
16Carrillo-Sepúlveda MA, Ceravolo GS, Fortes ZB, Carvalho MH, Tostes RC, Laurindo FR, et al. Thyroid hormone stimulates NO production via activation of the PI3K/Akt pathway in vascular myocytes. Cardiovasc Res. 2010;85:560-70.
17Vyakaranam S, Vanaparthy S, Nori S, Palarapu S, Bhongir AV. Study of insulin resistance in subclinical hypothyroidism. Int J Health Sci Res. 2014;4:147-53.
18Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med. 2013;61:1161-4.
19Zang H, Jiang F, Cheng X, Xu H, Hu X. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index. Endocr J. 2018;65:685-91.
20Zheng J, Liu M, Chen L, Yin F, Zhu X, Gou J, et al. Association between serum adropin level and coronary artery disease: a systematic review and meta-analysis. Cardiovasc Diagn Ther. 2019;9:1-7.
21Rezk MY, Atia RRAK. Adropin and irisin levels in a rat model of hypothyroidism. J Physiol Pathophysiol. 2020;11:1-8.
22Mogulkoc R, Dasdelen D, Baltaci SB, Baltaci AK, Sivrikaya A. The effect of thyroid dysfunction and treatment on adropin, asprosin and preptin levels in rats. Horm Mol Biol Clin Investig. 2020;42:37-42.
23Akbaba G, Koca E, Çınar N, Edgünlü T, Tosun K. Comparison of serum netrin-1. Nesfatin-1 and adropin levels in subclinical and overt hypothyroidism. Turk J Endocrinol Metab. 2018;22:57-7.
